Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01888874




Registration number
NCT01888874
Ethics application status
Date submitted
26/06/2013
Date registered
28/06/2013
Date last updated
17/11/2020

Titles & IDs
Public title
Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)
Scientific title
Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks in Combination With Methotrexate to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Alone
Secondary ID [1] 0 0
2012-003635-31
Secondary ID [2] 0 0
GLPG0634-CL-203 (DARWIN1)
Universal Trial Number (UTN)
Trial acronym
DARWIN1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - GLPG0634
Treatment: Drugs - Placebo

Placebo comparator: Placebo - Participants received GLPG0634 matching placebo capsules, orally, twice daily (BID) during Weeks 1 to 12. Participants who were responders (having at least 20 percent \[%\] improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 milligram (mg) once daily (QD) or 50 mg BID during Weeks 13 to 24.

Experimental: GLPG0634 50 mg QD - Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.

Experimental: GLPG0634 100 mg QD - Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.

Experimental: GLPG0634 200 mg QD - Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.

Experimental: GLPG0634 25 mg BID - Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.

Experimental: GLPG0634 50 mg BID - Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.

Experimental: GLPG0634 100 mg BID - Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.


Treatment: Drugs: GLPG0634
GLPG0634 capsules.

Treatment: Drugs: Placebo
Placebo capsules.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Achieving an American College of Rheumatology (ACR) 20 Response at Week 12
Timepoint [1] 0 0
Week 12
Secondary outcome [1] 0 0
Percentage of Participants Achieving an ACR20 Response at Week 24
Timepoint [1] 0 0
Week 24
Secondary outcome [2] 0 0
Percentage of Participants Achieving an ACR50 Response at Weeks 1, 2, 4, 8, 12, and 24
Timepoint [2] 0 0
Weeks 1, 2, 4, 8, 12, and 24
Secondary outcome [3] 0 0
Percentage of Participants Achieving an ACR70 Response at Weeks 1, 2, 4, 8, 12, and 24
Timepoint [3] 0 0
Weeks 1, 2, 4, 8, 12, and 24
Secondary outcome [4] 0 0
ACR N% Improvement (ACR-N) Response at Weeks 1, 2, 4, 8, 12, and 24
Timepoint [4] 0 0
Weeks 1, 2, 4, 8, 12, and 24
Secondary outcome [5] 0 0
Percentage of Participants With Disease Activity Score 28 Joints Corrected for CRP (DAS28 (CRP)) European League Against Rheumatism (EULAR) Response at Weeks 1, 2, 4, 8, 12, and 24
Timepoint [5] 0 0
Weeks 1, 2, 4, 8, 12, and 24
Secondary outcome [6] 0 0
Percentage of Participants Achieving ACR/EULAR Remission at Weeks 2, 4, 8, 12, and 24
Timepoint [6] 0 0
Weeks 2, 4, 8, 12, and 24
Secondary outcome [7] 0 0
Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 1, 2, 4, 8, 12, and 24
Timepoint [7] 0 0
Baseline and Weeks 1, 2, 4, 8, 12, and 24
Secondary outcome [8] 0 0
Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 1, 2, 4, 8, 12, and 24
Timepoint [8] 0 0
Baseline and Weeks 1, 2, 4, 8, 12, and 24
Secondary outcome [9] 0 0
Change From Baseline in Quality of Life Using the Functional Assessment of Chronic Illness Therapy (FACIT) at Weeks 4, 12, and 24
Timepoint [9] 0 0
Baseline and Weeks 4, 12, and 24
Secondary outcome [10] 0 0
Change From Baseline in Quality of Life Using the Short Form-36 (SF-36) Scores at Weeks 4, 12, and 24
Timepoint [10] 0 0
Baseline and Weeks 4, 12, and 24

Eligibility
Key inclusion criteria
* have a diagnosis of RA since at least 6 months and meeting the 2010 ACR/EULAR criteria of RA and ACR functional class I-III,
* have =6 swollen joints (from a 66 joint count) and =8 tender joints (from a 68 joint count) at Screening and at Baseline,
* Screening serum c-reactive protein =0.7 x upper limit of laboratory normal range (ULN),
* have received MTX for =6 months and have been on a stable dose (15 to 25 mg/week) of MTX for at least 4 weeks prior to Screening and willing to continue on their current regimen for the duration of the study. Stable doses of MTX as low as 10 mg/week are allowed when there is documented evidence of intolerance or safety issues at higher doses.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* current therapy with any disease-modifying anti-rheumatic drugs (DMARD) other than MTX,
* current or previous RA treatment with a biologic DMARD, with the exception of biologic DMARDs administered in a single clinical study setting more than 6 months prior to Screening (12 months for rituximab or other B cell depleting agents), where the biologic DMARD was effective, and if discontinued, this should not be due to lack of efficacy,
* previous treatment at any time with a cytotoxic agent, other than MTX, before Screening.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
17/07/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
14/05/2015
Sample size
Target
Accrual to date
Final
599
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
Monash Medical Centre - Clayton
Recruitment hospital [3] 0 0
Repatriation General Hospital - Daw Park
Recruitment hospital [4] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment postcode(s) [1] 0 0
- Camperdown
Recruitment postcode(s) [2] 0 0
- Clayton
Recruitment postcode(s) [3] 0 0
- Daw Park
Recruitment postcode(s) [4] 0 0
- Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Idaho
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
North Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Oklahoma
Country [14] 0 0
United States of America
State/province [14] 0 0
Pennsylvania
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
United States of America
State/province [16] 0 0
Washington
Country [17] 0 0
United States of America
State/province [17] 0 0
West Virginia
Country [18] 0 0
Argentina
State/province [18] 0 0
Buenos Aires
Country [19] 0 0
Argentina
State/province [19] 0 0
Cordoba
Country [20] 0 0
Argentina
State/province [20] 0 0
Quilmes
Country [21] 0 0
Argentina
State/province [21] 0 0
San Fernando
Country [22] 0 0
Argentina
State/province [22] 0 0
Tucuman
Country [23] 0 0
Austria
State/province [23] 0 0
Wien
Country [24] 0 0
Belgium
State/province [24] 0 0
Brussels
Country [25] 0 0
Belgium
State/province [25] 0 0
Hasselt
Country [26] 0 0
Belgium
State/province [26] 0 0
Kortrijk
Country [27] 0 0
Belgium
State/province [27] 0 0
Leuven
Country [28] 0 0
Belgium
State/province [28] 0 0
Liege
Country [29] 0 0
Bulgaria
State/province [29] 0 0
Plovdiv
Country [30] 0 0
Bulgaria
State/province [30] 0 0
Ruse
Country [31] 0 0
Bulgaria
State/province [31] 0 0
Sofia
Country [32] 0 0
Chile
State/province [32] 0 0
Concepcion
Country [33] 0 0
Chile
State/province [33] 0 0
Santiago
Country [34] 0 0
Chile
State/province [34] 0 0
Temuco
Country [35] 0 0
Colombia
State/province [35] 0 0
Barranquilla
Country [36] 0 0
Colombia
State/province [36] 0 0
Bogota
Country [37] 0 0
Colombia
State/province [37] 0 0
Bucaramanga
Country [38] 0 0
Colombia
State/province [38] 0 0
Cali
Country [39] 0 0
Colombia
State/province [39] 0 0
Cundinamarca
Country [40] 0 0
Colombia
State/province [40] 0 0
Medellin
Country [41] 0 0
Czechia
State/province [41] 0 0
Brno
Country [42] 0 0
Czechia
State/province [42] 0 0
Kladno
Country [43] 0 0
Czechia
State/province [43] 0 0
Praha-Nusle
Country [44] 0 0
Czechia
State/province [44] 0 0
Uherske Hradiste
Country [45] 0 0
Czechia
State/province [45] 0 0
Zlin
Country [46] 0 0
France
State/province [46] 0 0
Strasbourg
Country [47] 0 0
Germany
State/province [47] 0 0
Berlin
Country [48] 0 0
Germany
State/province [48] 0 0
Frankfurt
Country [49] 0 0
Germany
State/province [49] 0 0
Hamburg
Country [50] 0 0
Germany
State/province [50] 0 0
Herne
Country [51] 0 0
Guatemala
State/province [51] 0 0
Guatemala City
Country [52] 0 0
Guatemala
State/province [52] 0 0
Guatemala
Country [53] 0 0
Hungary
State/province [53] 0 0
Balatonfured
Country [54] 0 0
Hungary
State/province [54] 0 0
Budapest
Country [55] 0 0
Hungary
State/province [55] 0 0
Eger
Country [56] 0 0
Hungary
State/province [56] 0 0
Gyula
Country [57] 0 0
Hungary
State/province [57] 0 0
Veszprem
Country [58] 0 0
Israel
State/province [58] 0 0
Haifa
Country [59] 0 0
Israel
State/province [59] 0 0
Ramat Gan
Country [60] 0 0
Latvia
State/province [60] 0 0
Adazi
Country [61] 0 0
Latvia
State/province [61] 0 0
Daugavplis
Country [62] 0 0
Latvia
State/province [62] 0 0
Liepaja
Country [63] 0 0
Latvia
State/province [63] 0 0
Riga
Country [64] 0 0
Mexico
State/province [64] 0 0
Guadalajara
Country [65] 0 0
Mexico
State/province [65] 0 0
Mexico
Country [66] 0 0
Mexico
State/province [66] 0 0
Monterrey
Country [67] 0 0
Mexico
State/province [67] 0 0
San Luis Potosi
Country [68] 0 0
Moldova, Republic of
State/province [68] 0 0
Chisinau
Country [69] 0 0
New Zealand
State/province [69] 0 0
Auckland
Country [70] 0 0
New Zealand
State/province [70] 0 0
Hamilton
Country [71] 0 0
New Zealand
State/province [71] 0 0
Timaru
Country [72] 0 0
Poland
State/province [72] 0 0
Bialystok
Country [73] 0 0
Poland
State/province [73] 0 0
Bytom
Country [74] 0 0
Poland
State/province [74] 0 0
Katowice
Country [75] 0 0
Poland
State/province [75] 0 0
Krakow
Country [76] 0 0
Poland
State/province [76] 0 0
Skierniewice
Country [77] 0 0
Poland
State/province [77] 0 0
Sroda Wielkopolska
Country [78] 0 0
Poland
State/province [78] 0 0
Starachowice
Country [79] 0 0
Poland
State/province [79] 0 0
Torun
Country [80] 0 0
Poland
State/province [80] 0 0
Warsaw
Country [81] 0 0
Poland
State/province [81] 0 0
Wroclaw
Country [82] 0 0
Russian Federation
State/province [82] 0 0
Moscow
Country [83] 0 0
Russian Federation
State/province [83] 0 0
Nizhniy Novgorod
Country [84] 0 0
Russian Federation
State/province [84] 0 0
Ryazan
Country [85] 0 0
Russian Federation
State/province [85] 0 0
St Petersburg
Country [86] 0 0
Russian Federation
State/province [86] 0 0
Vladimir
Country [87] 0 0
Spain
State/province [87] 0 0
Cordoba
Country [88] 0 0
Spain
State/province [88] 0 0
Coruña
Country [89] 0 0
Spain
State/province [89] 0 0
Elche
Country [90] 0 0
Spain
State/province [90] 0 0
Mostoles
Country [91] 0 0
Spain
State/province [91] 0 0
Sabadell
Country [92] 0 0
Spain
State/province [92] 0 0
Sevilla
Country [93] 0 0
Ukraine
State/province [93] 0 0
Donetsk
Country [94] 0 0
Ukraine
State/province [94] 0 0
Kharkiv
Country [95] 0 0
Ukraine
State/province [95] 0 0
Kiev
Country [96] 0 0
Ukraine
State/province [96] 0 0
Kyiv
Country [97] 0 0
Ukraine
State/province [97] 0 0
Lutsk

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Galapagos NV
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Participants suffering from active rheumatoid arthritis despite continued treatment with methotrexate were evaluated for improvement of disease activity (efficacy) when taking GLPG0634 (3 different doses - 50 milligram \[mg\], 100 mg and 200 mg daily -, each evaluated as once daily \[QD\] and twice daily \[BID\] regimen) or matching placebo for 24 weeks.

•During the course of the study, patients were also examined for any side effects that could occur (safety and tolerability), and the amount of GLPG0634 present in the blood (Pharmacokinetics) as well as the effects of GLPG0634 on disease- and mechanism of action-related parameters in the blood (Pharmacodynamics) were determined. Also, the effects of different doses and dose regiments of GLPG0634 administration on participants' disability, fatigue, and quality of life were evaluated.
Trial website
https://clinicaltrials.gov/study/NCT01888874
Trial related presentations / publications
Combe B, Besuyen R, Gomez-Centeno A, Matsubara T, Sancho Jimenez JJ, Yin Z, Buch MH. Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis. Rheumatol Ther. 2023 Feb;10(1):35-51. doi: 10.1007/s40744-022-00494-1. Epub 2022 Oct 7.
Tarrant JM, Galien R, Li W, Goyal L, Pan Y, Hawtin R, Zhang W, Van der Aa A, Taylor PC. Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials. Rheumatol Ther. 2020 Mar;7(1):173-190. doi: 10.1007/s40744-019-00192-5. Epub 2020 Jan 7.
Westhovens R, Taylor PC, Alten R, Pavlova D, Enriquez-Sosa F, Mazur M, Greenwald M, Van der Aa A, Vanhoutte F, Tasset C, Harrison P. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis. 2017 Jun;76(6):998-1008. doi: 10.1136/annrheumdis-2016-210104. Epub 2016 Dec 19.
Public notes

Contacts
Principal investigator
Name 0 0
Galapagos Study Director
Address 0 0
Galapagos NV
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01888874